Subscribe To
MRNA / Moderna stock plummets on 3Q loss and weak sales guidance
![Moderna stock plummets on 3Q loss and weak sales guidance](https://cdn.snapi.dev/images/v1/w/o/shutterstock-1891094320-2136807.jpg)
MRNA News
![Moderna May Be Facing Its Toughest Moment Ever. Time to Sell? Moderna May Be Facing Its Toughest Moment Ever. Time to Sell?](https://cdn.snapi.dev/images/v1/s/e/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f7536882fgettyimages-1316264191jpgopresizew400h400-2140362.jpg)
By The Motley Fool
November 4, 2023
Moderna May Be Facing Its Toughest Moment Ever. Time to Sell?
Moderna reported a billion-dollar loss in the third quarter and began downsizing its manufacturing infrastructure to match lower levels of vaccine dem more_horizontal
![Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say](https://cdn.snapi.dev/images/v1/v/9/default37-2140239.jpg)
By Zacks Investment Research
November 3, 2023
Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended September 2023, it might be worth cons more_horizontal
![Moderna CEO discusses earnings and how the company aims to break even by 2026 Moderna CEO discusses earnings and how the company aims to break even by 2026](https://cdn.snapi.dev/images/v1/7/y/moderna-ceo-discusses-earnings-and-how-the-company-aims-to-break-even-by-2026-2138052.jpg)
By Yahoo Finance
November 2, 2023
Moderna CEO discusses earnings and how the company aims to break even by 2026
While boasting a third-quarter revenue beat, biotech firm Moderna (MRNA) reported an overwhelmingly higher-than-expected loss of $9.53 per share. Its more_horizontal
![Moderna Shares Slide After Posting a Loss on Falling COVID-19 Vaccine Sales and Production Moderna Shares Slide After Posting a Loss on Falling COVID-19 Vaccine Sales and Production](https://cdn.snapi.dev/images/v1/g/n/gettyimages-1240236804-59588048fcf547e1a6f9bb85cd798670-2137898.jpg)
By Investopedia
November 2, 2023
Moderna Shares Slide After Posting a Loss on Falling COVID-19 Vaccine Sales and Production
Moderna (MRNA) shares tumbled over 6% Thursday after reporting a steep loss as the drug maker lost sales and cut back on making its COVID-19 vaccine, more_horizontal
![Moderna, Inc. (MRNA) Q3 2023 Earnings Call Transcript Moderna, Inc. (MRNA) Q3 2023 Earnings Call Transcript](https://cdn.snapi.dev/images/v1/j/g/transcript44-2136924.jpg)
By Seeking Alpha
November 2, 2023
Moderna, Inc. (MRNA) Q3 2023 Earnings Call Transcript
Moderna, Inc. (NASDAQ:MRNA ) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head of Investor Rela more_horizontal
![Moderna stock plummets on 3Q loss and weak sales guidance Moderna stock plummets on 3Q loss and weak sales guidance](https://cdn.snapi.dev/images/v1/w/o/shutterstock-1891094320-2136807.jpg)
By Proactive Investors
November 2, 2023
Moderna stock plummets on 3Q loss and weak sales guidance
Moderna Therapeutics Inc (NASDAQ:MRNA) stock moved lower on Thursday after the drugmaker's weak full-year sales forecast and a significant loss for th more_horizontal
![Moderna posts quarterly loss as company takes $1.3 billion write-down on unused Covid shots Moderna posts quarterly loss as company takes $1.3 billion write-down on unused Covid shots](https://cdn.snapi.dev/images/v1/o/r/moderna-posts-quarterly-loss-as-company-takes-13-billion-write-down-on-unused-covid-shots-2135875.jpg)
By CNBC Television
November 2, 2023
Moderna posts quarterly loss as company takes $1.3 billion write-down on unused Covid shots
CNBC's Becky Quick reports on the company's quarterly earnings results. more_horizontal
![Moderna revenue tops expectations, expects to return to sales growth in 2025 Moderna revenue tops expectations, expects to return to sales growth in 2025](https://cdn.snapi.dev/images/v1/0/n/c6q3qal4jfo4jjut7dxiwdyfki-2135420.jpg)
By Reuters
November 2, 2023
Moderna revenue tops expectations, expects to return to sales growth in 2025
Moderna on Thursday said it expected 2023 revenue of at least $6 billion, a decline reflecting weaker demand for COVID-19 vaccines this year, but that more_horizontal